Heart Rate Is a Marker of Amiodarone Mortality Reduction in Severe Heart Failure  by Nul, Daniel R. et al.
CLINICAL STUDIES HEART FAILURE
Heart Rate Is a Marker of Amiodarone Mortality Reduction in Severe
Heart Failure
DANIEL R. NUL, MD, HERNA´N C. DOVAL, MD, HUGO O. GRANCELLI, MD,
SERGIO D. VARINI, MD, SAUL SOIFER, MD, SERGIO V. PERRONE, MD,
NOEMI´ PRIETO, MD, OMAR SCAPIN, MD, ON BEHALF OF THE GESICA-GEMA INVESTIGATORS*
Buenos Aires, Argentina
Objectives. The impact of amiodarone on mortality in patients
with severe congestive heart failure (CHF) (New York Heart
Association functional classes II [advanced], III and IV; left
ventricular ejection fraction <35%) in the Grupo de Estudio de la
Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
trial was analyzed in relation to initial mean baseline heart rate
(BHR) and its change after 6 months of follow-up.
Background. Trials of amiodarone therapy in CHF have pro-
duced discordant results, suggesting that the effect is not uniform
in all patient subgroups with regard to survival.
Methods. The present analysis was carried out in 516 patients
randomized to receive amiodarone, 300 mg/day (n 5 260), or
nonantiarrhythmic therapy (n 5 256, control group) and followed
up for 2 years. Survival was evaluated for patients with a BHR
>290 beats/min (control: n 5 132; amiodarone: n 5 122) and <90
beats/min (control: n 5 124; amiodarone: n 5 138). Survival was
also analyzed according to heart rate reduction at 6 months for
367 patients.
Results. For patients with a BHR >290 beats/min, amiodarone
therapy reduced mortality to 38.4% compared with 62.4% in
control patients (relative risk [RR] 0.55, 95% confidence interval
[CI] 0.35 to 0.95, p < 0.002). Both sudden death (RR 0.46, 95% CI
0.24 to 0.90, p < 0.02) and progressive heart failure death (RR
0.60, 95% CI 0.30 to 1.03, p < 0.06) were reduced, and functional
capacity was improved. In patients with a BHR <90 beats/min,
amiodarone did not alter survival. Among 367 patients who
completed 6 months of follow-up, amiodarone reduced 2-year
mortality only in those with a BHR >290 beats/min, which was
reduced at 6 months.
Conclusions. Elevated rest heart rates in severe CHF identify a
subgroup of patients who benefit from treatment with amioda-
rone. Amiodarone-induced heart rate slowing may be an impor-
tant benefit for patients.
(J Am Coll Cardiol 1997;29:1199–205)
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The prevalence of ventricular arrhythmias and sudden death in
severe congestive heart failure (CHF) has focused attention on
antiarrhythmic therapy as a means for reducing mortality
(1–5). Amiodarone has emerged as the drug of choice because
of its potent antiarrhythmic effects and low potential for
proarrhythmic and negative inotropic effects, as opposed to
other antiarrhythmic agents (6–9). Grupo de Estudio de la
Sobrevida en la Insuficiecia Cardiaca en Argentina (GESICA),
a randomized trial of low dose amiodarone in severe CHF
reported a 28% reduction in 2-year overall mortality (10). The
mortality reduction was due not only to a decrease in sudden
death, but also to a reduction in death from progressive heart
failure. The reduction in mortality was independent of the
severity of ambient ventricular arrhythmia on admission, and
was associated with a decrease in hospital admissions due to
heart failure and an improvement of functional capacity in
amiodarone-treated patients. The results suggest benefit be-
yond that expected from purely an antiarrhythmic effect.
In addition to its antiarrhythmic action, amiodarone slows
the sinus heart rate. The precise cause of the reduction in rate
is unclear, but it may be due to depression of sinus node
automaticity and slowing of atrioventricular node conduction
(in the case of atrial fibrillation) mediated in part by noncom-
petitive beta-blockade (11,12).
An inappropriate, rapid heart rate in CHF may reflect
abnormal activation of the sympathetic nervous system, which
might be reduced by amiodarone (13,14). We hypothesized
that the benefit of amiodarone may be mediated in part by a
reduction in heart rate. The objective of this report was to
retrospectively analyze the mortality reduction produced by
amiodarone in GESICA, relative to the baseline heart rate
(BHR) and its reduction during treatment.
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Methods
Study design and patient selection. The design of the
GESICA trial and the characteristics of the patients enrolled
have been previously published elsewhere and will be briefly
summarized (10). The present analysis was carried out in the
entire study group of 516 patients. All patients had advanced
CHF with a marked reduction of left ventricular systolic
function that was adequately treated with a low sodium diet,
diuretics, digitalis and angiotensin-converting enzyme inhibi-
tors, without antiarrhythmic treatment. Patients were required
to have stable functional capacity judged by a combination of
the Canadian Cardiovascular Society criteria and the Specific
Activity Scale, as equivalent to New York Heart Association
functional class II (advanced), III or IV.
Also, at least two of the three following indexes of systolic
myocardial dysfunction had to be present: chest radiograph
cardiothoracic ratio .0.55, ejection fraction measured by
radioisotope method #0.35 and end-diastolic echocardio-
graphic diameter $3.2 cm/m2.
Exclusion criteria were amiodarone treatment during the
preceding 3 months; thyroid dysfunction; severe respiratory
failure; concomitant serious disease; mitral stenosis, aortic
stenosis and/or hypertrophic or restrictive cardiomyopathy;
recent instability with angina, myocardial infarction, heart
failure onset or syncope within the previous 3 months; atrio-
ventricular conduction disorder; history of sustained ventricu-
lar tachycardia or ventricular fibrillation; and asymptomatic
ventricular tachycardia for .10 beats with heart rate faster
than 100 beats/min.
The study was approved by the Institutional Review Board
of each hospital, and each patient gave informed consent. An
independent scientific and ethics committee monitored the
progress of the study.
The study was conducted in 26 hospitals in Argentina from
December 1989 to March 1993. This was a prospective,
parallel, randomized and stratified trial according to the
presence of nonsustained ventricular tachycardia in the initial
24-h Holter recording.
The control group (n 5 256) continued to receive nonan-
tiarrhythmic therapy for heart failure. The amiodarone group
(n 5 260) received amiodarone at a dose of 600 mg/day for 14
days, and then 300 mg/day was added to their standard heart
failure therapy. Patients were seen at 3, 6, 12, 18 and 24 months
for follow-up. When a patient required heart surgery or
transplantation, follow-up was discontinued on the day of the
surgical procedure.
End points were total mortality, cardiopulmonary resusci-
tation and symptomatic sustained ventricular tachycardia.
Death was attributed to progressive heart failure, sudden
death (death within an hour of presentation of new symptoms),
unknown (no means of establishing with certainty the cause of
death) and noncardiac causes. The cause of death was deter-
mined by investigators at the coordinating center who had no
knowledge of the assigned treatment group. The study was
terminated by the steering committee, which acted on the
advice of the scientific and ethics committee, after the second
prespecified analysis.
Analysis according to heart rate. Heart rate was deter-
mined from a physical examination. In the presence of atrial
fibrillation, the average heart rate for 1 min was assessed. The
effect of BHR was evaluated by stratifying each group (amio-
darone and control) according to a mean BHR $90 and ,90
beats/min, respectively. Thus, four groups were established,
each comprising approximately the same number of patients.
In addition, 367 patients completed 6 months of follow-up,
at which time rest heart rate was re-evaluated. For the
purposes of analysis, those patients whose rest heart rate at 6
months of follow-up was less than the BHR were considered to
have had a reduction in heart rate.
Statistical analysis. The Kaplan-Meier method was used
to construct life-table curves, and the curves were compared
using a two-tailed log-rank test.
Percent reduction in mortality was reported as: (1 2 RR) 3
100, where RR is the estimated relative risk of an event in the
compared groups. To adjust for baseline differences, the
proportional hazards model (Cox regression model) was used,
incorporating significant variables (p , 0.05) according to the
likelihood ratio test.
To compare differences between groups, the Student t test
was used for evaluation of continuous variables and the
chi-square test was used for proportions.
Follow-up, including death and censored patients, ranged
from 2 to 24 months (average 13). The 2-year actuarial
mortality rate was 48%. At the end of the trial, 19 patients
(3.7%) had been lost to follow-up and were censored from the
analysis on the last known date of follow-up: 9 patients with a
BHR ,90 beats/min (5 in control group and 4 in amiodarone
group) and 10 with a BHR $90 beats/min (7 in control group
and 3 in amiodarone group). In 16 patients, follow-up was
concluded at the time of heart transplantation: 5 patients with
a BHR ,90 beats/min (2 in control group and 3 in amiodarone
group) and 11 patients with a BHR $90 beats/min (5 in control
group and 6 in amiodarone group). In six patients, follow-up
was concluded at the time of other cardiovascular surgery:
three patients with a BHR ,90 beats/min (all in control group)
and 3 patients with a BHR $90 beats/min.
Abbreviations and Acronyms
BHR 5 baseline heart rate
CHF 5 congestive heart failure
CHF-STAT 5 Congestive Heart Failure—Survival Trial
of Antiarrhythmic Therapy
CI 5 confidence interval
CIBIS 5 Cardiac Insufficiency BIsoprolol Study
GESICA 5 Grupo de Estudio de la Sobrevida en la
Insuficiencia Cardiaca en Argentina
RR 5 relative risk
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Results
Clinical characteristics and baseline heart rate. From the
total group of 516 patients, 254 had a BHR $90 beats/min
(control: n 5 132; amiodarone: n 5 122) and 262 patients had
a BHR ,90 beats/min (control: n 5 124; amiodarone: n 5
138).
Baseline clinical characteristics differed among the groups
(Table 1). Patients with a BHR $90 beats/min had evidence of
worse heart failure compared with patients with a BHR ,90
beats/min, as indicated by a lower left ventricular ejection
fraction (17.5% vs. 20.3%, p , 0.003), lower systolic blood
pressure (p , 0.005), lower serum sodium concentration (p ,
0.003), worse functional class (p , 0.001), greater evidence of
right heart failure (p , 0.0001) and higher diuretic require-
ment (p , 0.003).
However, there were no differences between control and
amiodarone-treated patients in the group with a BHR .90
beats/min (Table 2) or in the group with a BHR ,90 beats/
min.
Baseline heart rate, mortality and amiodarone treatment.
For the entire study group, the 2-year mortality rate was higher
in patients with a BHR $90 beats/min (50.8%) compared with
patients with a BHR ,90 beats/min (44.8%) (p , 0.01). For
patients with a BHR $90 beats/min, the mortality rate was
lower in amiodarone-treated patients compared with control
patients (38.4% vs. 62.4%, RR 0.55, 95% confidence interval
[CI] 0.35 to 0.95, p , 0.002) (Table 3, Fig. 1).
In patients with a BHR ,90 beats/min, amiodarone-treated
patients had a mortality rate similar to that of the control
patients (44.8% vs. 44.7%, RR 1.0, 95% CI 0.74 to 1.45, p ,
0.97) (Table 3, Fig. 1).
Patient division in quintiles according to BHR indicates
that mortality reduction with amiodarone was associated with
a higher BHR, being highly significant in the higher quintile
with a BHR $100 beats/min (RR 0.35, 95% CI 0.19 to 0.67,
p , 0.001). At the opposite end, in the lowest quintile with a
BHR ,76 beats/min, a trend toward an increase in risk in
amiodarone-treated patients was observed (RR 1.34, 95% CI
0.68 to 2.67, p , 0.35) (Fig. 2).
Baseline heart rate, amiodarone treatment and mode of
death. A significant reduction in sudden death was observed
in patients with a BHR $90 beats/min treated with amioda-
rone (RR 0.46, 95% CI 0.24 to 0.90, p , 0.02). Death due to
Table 1. Baseline Heart Rate and Clinical Characteristics
HR $90
beats/min
(n 5 254)
HR ,90
beats/min
(n 5 262)
p
Value*
Age (yr) 57.8 6 13 60.5 6 12 0.01
HR (beats/min) 102 6 11 77.6 6 7 0.0001
SBP (mm Hg) 113.9 6 23 119.2 6 20 0.005
Serum Na1 (mmol/liter) 136.9 6 5 138.1 6 4 0.007
Serum K1 (mmol/liter) 4.2 6 0.4 4.2 6 0.4 0.96
Serum urea (mg/dl) 46.9 6 17 47 6 16 0.95
LVEF (%) 17.5 6 7.2 20.3 6 7.4 0.003
Diastolic diam (cm/m2) 3.80 6 0.5 3.83 6 0.5 0.53
Male 83.0 73.3 0.02
NYHA class
II 15.4 26.3
III 46.0 50.4
IV 38.6 23.3 0.0001
Previous MI 39.4 41.6 0.6
Right HF† 57.5 31.3 0.0001
AF 27.1 22.5 0.24
NSVT (24-h Holter) 36.2 30.9 0.23
Drug Therapy
Digitalis 77.6 75.2 0.52
Furosemide 92.1 91.2 0.83
mg/day 42.2 6 24 36.4 6 21 ,0.003
Enalapril 87.8 94.2 0.02
mg/day 10.2 6 6 9.32 6 5 ,0.011
Nitrites 39.4 30.2 0.03
Anticoagulants 33.1 28.6 0.27
*p , 0.01 was considered significant by multiple comparisons. †Defined as
jugular venous distension, edema and hepatomegaly. Data presented are mean
value 6 SD or percent of patients. AF 5 atrial fibrillation; diam 5 diameter;
HF 5 heart failure; HR 5 heart rate; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction; NSVT 5 nonsustained ventricular tachycardia;
NYHA 5 New York Heart Association; SBP 5 systolic blood pressure.
Table 2. Clinical Characteristics in Patients With Baseline Heart
Rate $90 beats/min
Control
Group
(n 5 132)
Amiodarone
Group
(n 5 122)
p
Value*
Age (yr) 58.1 6 14 58 6 12 0.73
HR (beats/min) 102.7 6 12 101.3 6 10 0.31
SBP (mm Hg) 111.5 6 23 116.4 6 22 0.09
Serum Na1 (mmol/liter) 136.9 6 6 137.5 6 5 0.86
Serum K1 (mmol/liter) 4.2 6 0.4 4.2 6 0.4 0.22
Serum urea (mg/dl) 47.6 6 17 46.2 6 17 0.51
LVEF (%) 17 6 7.5 17.9 6 6.9 0.49
Diastolic diam (cm/m2) 3.83 6 0.52 3.77 6 0.43 0.34
Male 81.0 85.0 0.56
NYHA class
II 12.9 18.0
III 44.0 46.7
IV 43.2 35.2 0.28
Previous MI 39.4 39.3 0.90
Right HF† 51.5 63.9 0.05
AF 27.3 27.0 0.44
NSVT (24-h Holter) 36.4 36.0 0.96
Drug Therapy
Digitalis 78.8 76.2 0.93
Furosemide 93.2 91.0 0.67
mg/day 44.9 6 22 46.6 6 19 0.56
Enalapril 85.6 90.2 0.35
mg/day 10.8 6 7 9.51 6 5 0.14
Nitrites 38.6 40.16 0.80
Anticoagulants 34.1 32.0 0.71
*p , 0.01 was considered significant by multiple comparisons. †Defined as
jugular venous distension, edema and hepatomegaly. Data presented are mean
value 6 SD. Abbreviations as in Table 1.
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progressive heart failure was also lower in this group of
patients, but this difference was of borderline statistical signif-
icance (RR 0.60, 95% CI 0.30 to 1.03, p , 0.06). In patients
with a BHR ,90 beats/min, no significant differences in
sudden death or death from progressive heart failure were
observed (Table 3).
Heart rate modification. A total of 367 patients had their
rest heart rate determined at 6 months of follow-up. The BHR
at the beginning of the study was similar in the amiodarone and
control groups. In those patients with a BHR $90 beats/min
(188 patients, mean heart rate 100.9 6 10 beats/min), heart
rate was reduced at 6 months by 12.7 6 16 beats/min in the
amiodarone group and by 7.6 6 13 beats/min in the control
group (p , 0.02). In 179 patients with a BHR ,90 beats/min
(mean heart rate 76.7 6 7 beats/min), there was a trend toward
an increased heart rate at 6 months, which was greater in the
control group (6.8 6 12 beats/min) than in the amiodarone
group (2.2 6 12 beats/min) (p , 0.01). There were no
differences between the groups with regard to medication
changes over follow-up. Amiodarone withdrawal occurred in
only 15 patients.
Heart rate reduction and mortality. Of the 137 patients
with a BHR $90 beats/min and whose heart rate decreased at
6 months of follow-up, the mortality rate was significantly
lower in those patients treated with amiodarone (21.7%)
compared with control patients (53.8%) (p , 0.002). In
patients with a BHR $90 beats/min and whose heart rate was
not decreased at 6 months of follow-up, the mortality rate was
similar for amiodarone-treated (55.2%) and control patients
(55.9%). Among patients with a BHR ,90 beats/min, there
were no differences in mortality, regardless of changes in heart
rate at 6 months of follow-up.
Functional capacity modifications. Baseline functional ca-
pacity was similar in the amiodarone and control groups. In
patients with a BHR $90 beats/min, the proportion of patients
in functional class I or II at 6 months was greater in the
amiodarone group than in the control group (51.3% vs.
31.5%), and the proportion of patients in functional class IV
was lower in the amiodarone group than in the control group
(17.8% vs. 33.7%) (p , 0.02). In patients with a BHR ,90
beats/min, no differences were observed in functional capacity
at 6 months between the amiodarone and control groups.
Figure 1. Kaplan-Meier curves showing survival differences between
amiodarone-treated and control patients according to (left) BHR ,90
beats/min and (right) BHR $90 beats/min.
Figure 2. Patient division in quintiles according to BHR and 2-year
actuarial mortality in amiodarone-treated and control patients. The
arrows on the abcissa indicate the BHR range in each quintile. This
graph shows that the higher the BHR, the greater the mortality
reduction in the amiodarone group. B/m 5 beats/min.
Table 3. Initial Baseline Heart Rate, Mortality and Cause of Death
HR ,90 beats/min HR $90 beats/min
Control
Group
[no. (%)]
Amiodarone
Group
[no. (%)]
RR
(95% CI)
p Value
(two-sided)
Control
Group
[no. (%)]
Amiodarone
Group
[no. (%)]
RR
(95% CI)
p Value
(two-sided)
Randomized patients 124 (100) 138 (100) 132 (100) 122 (100)
Overall death 41 (33.1) 48 (34.8) 1.02 (0.74–1.45) 0.97 65 (49.2) 39 (32) 0.55 (0.35–0.95) 0.002
Sudden death 13 (10.5) 19 (13.8) 1.25 (0.39–1.62) 0.52 26 (19.7) 13 (10.7) 0.46 (0.24–0.90) 0.02
Progressive HF 18 (14.5) 22 (15.9) 1.05 (0.51–1.76) 0.85 34 (25.8) 22 (18) 0.60 (0.30–1.03) 0.06
Unknown 7 (5.6) 4 (2.9) 4 (3) 3 (2.5)
Other 3 (2.4) 3 (2.2) 1 (0.75) 1 (0.81)
CI 5 confidence interval; HR 5 heart rate; RR 5 relative risk.
1202 NUL ET AL. JACC Vol. 29, No. 6
AMIODARONE THERAPY FOR HEART FAILURE May 1997:1199–205
Discussion
In the present report the addition of low dose amiodarone
to conventional therapy in severe CHF decreased mortality,
but only among patients with a high rest heart rate at baseline.
Amiodarone strikingly reduced 2-year overall mortality in
patients with a BHR $90 beats/min, but had no impact on
survival in patients with a BHR ,90 beats/min. The beneficial
effect was due to a decrease in both sudden death and death
from progressive heart failure. Furthermore, for patients sur-
viving for 6 months, the benefit in the 2-year survival rate and
improved functional class was confined to those whose heart
rate was reduced during follow-up.
Baseline heart rate and mortality. A rapid heart rate is
associated with a variety of prognostic factors indicative of
worse heart failure and greater mortality. Interestingly, in the
patients treated with amiodarone, this was not the case;
mortality was similar across all BHR ranges. Therefore, the
higher the initial rest heart rate, the greater the benefit
observed from therapy with amiodarone (Fig. 2). In the highest
quintile with a BHR $100 beats/min, the mortality risk reduc-
tion was 65%, with the narrowest CI. As previously reported,
in the entire GESICA trial group, there was a favorable trend
toward a reduction in sudden and progressive heart failure
deaths, which did not attain statistical significance (10). In the
present report reductions in these end points were greater and
achieved statistical significance in patients with a BHR $90
beats/min. A tendency toward increased mortality in the lowest
quintile with a BHR ,76 beats/min (Fig. 2) could suggest that
bradyarrhythmias were increased in this group, contributing to
sudden death. This seems unlikely, however, because the mode
of death (sudden vs. progressive heart failure) in patients with
a BHR ,76 beats/min was similar in those treated with
amiodarone compared with control patients.
Amiodarone’s effect in congestive heart failure. Amioda-
rone is a unique and complex drug with multiple effects. It is
difficult to determine which of its effects might be related to
our findings. In contrast to many antiarrhythmic drugs, amio-
darone has been effective in several patient groups and has not
been associated with increased mortality (8). Its most obvious
direct electrophysiologic effect is prolongation of the action
potential duration and repolarization time (class III antiar-
rhythmic effect). Despite an association of QT prolongation
with malignant ventricular arrhythmias, amiodarone is the
antiarrhythmic agent that has the least proarrhythmic effect,
possibly due to more uniform prolongation of myocardial
repolarization resulting in a decrease of QT dispersion (15–
18). Sudden death reduction in patients with high heart rates
may be explained by an antiarrhythmic or antifibrillatory effect.
However, an antiarrhythmic effect does not account for all of
our findings.
In the present study functional capacity improved, hospital
admissions for heart failure were reduced and mortality due to
progressive heart failure was diminished. This can be con-
nected to several studies showing that therapy, even with lower
amiodarone dose, increases left ventricular ejection fraction
(19–22).
In another large amiodarone trial involving milder heart
failure Congestive Heart Failure—Survival Trial of Antiar-
rhythmic Therapy (CHF-STAT), although neutral survival
results were reported, a remarkable finding was that ejection
fraction increased by 42% at 6 months and that improvement
was maintained at 2 years (19). The highest increase in ejection
fraction was reported in patients with the greatest heart rate
reduction, who showed a favorable survival trend (22). That
trend is more significant in patients with nonischemic causes of
heart failure. Although randomization was not balanced for
etiology in the GESICA trial, results were similar anyway, and
it does not explain contrasting results between both trials (10).
The present analysis provides further evidence that differ-
ences in the severity of heart failure are a major reason for the
discrepant findings of the CHF-STAT and GESICA studies.
Patients in GESICA had more severe CHF with an average
BHR of 90 beats/min for the entire study group, compared
with 80 beats/min in CHF-STAT. Accordingly, if only the
patients with a high BHR and heart rate reduction during
treatment benefit, the neutral results in the CHF-STAT would
be expected. Heart rate reduction with the amiodarone dose
used in the GESICA trial was observed at 3 months of therapy,
attained a steady state after 6 months and was maintained
during the remainder of follow-up. Patients with a higher BHR
showed a more dramatic heart rate reduction during amioda-
rone treatment. A slighter decrease in mean heart rate was
observed in the control group with a BHR $90 beats/min and
might be interpreted as an indication of improved clinical
condition in survivors after 6 months.
Heart rate reduction hypothesis. The precise nature of
amiodarone-induced bradycardia remains unclear, but it may
result from direct depression of sinus node automaticity and
from noncompetitive antiadrenergic action (23). The antiad-
renergic effect of amiodarone has been suggested to result
from inhibition of adenylate cyclase formation and a reduction
in the number of beta-adrenergic receptors, an effect that
becomes more prominent after long-term amiodarone treat-
ment (11). This raises the possibility that beneficial effects
could be mediated by prevention of catecholamine toxicity and
improved myocardial energetics, as has been suggested for
therapy with beta-adrenergic blocking agents in heart failure
(24,25). These effects are more likely to have an impact on
patients with severe CHF who have greater sympathetic acti-
vation, higher heart rates and the most dramatic heart rate
reduction during treatment. In the Cardiac Insufficiency BIso-
prolol Study (CIBIS), beneficial effects included an increase in
ejection fraction, a reduction in heart rate, a decrease in
hospital admissions due to heart failure and a beneficial trend
toward improved survival in nonischemic patients (26). Re-
cently, pooled results from Carvedilol trials reported a marked
reduction in mortality with the use of this beta-blocker in
patients with CHF (27). Interestingly, mortality reduction was
clearer in patients with a BHR .82 beats/min (RR 0.26, 95%
CI 0.12 to 0.55) and was not related to the etiology of heart
1203JACC Vol. 29, No. 6 NUL ET AL.
May 1997:1199–205 AMIODARONE THERAPY FOR HEART FAILURE
failure. These trials include patients with less severe heart
failure than in GESICA, in which beta-adrenergic blocking
therapy would have been difficult to initiate because of the
severity of heart failure.
Several agents used for the treatment of heart failure have
been shown to increase ejection fraction and functional capac-
ity, but this did not necessarily improve survival (28–30). It is
possible that heart rate reduction by itself is responsible for the
improvement in ventricular function with amiodarone
(14,24,25). An abnormal force–frequency relation in failing
myocardium results in further depression of contractility at fast
heart rates (31). Amiodarone-induced heart rate slowing may
improve cardiac function, and prolongation of the action
potential duration may also have an inotropic effect owing to
greater intracellular calcium availability. A longer diastolic
filling period also promotes greater coronary blood flow, which
is likely to reduce ischemia. Amiodarone also has vasodilating
properties that could be beneficial.
Clinical implications. Our analysis was retrospective. It
may be helpful in future heart failure studies with amiodarone
or heart rate–reducing agents to stratify the randomization
according to heart rate to further address this issue.
These results have important clinical implications. We
suggest that chronic amiodarone therapy be recommended for
patients with CHF who have high rest heart rates and avoided
for those with slower rates. Furthermore, because many of
amiodarone’s side effects are dose related, heart rate reduction
can potentially be used as a guide to adjust the amiodarone
dose to obtain the best risk–benefit relation for improving
heart failure and reducing mortality.
We thank the medical investigators who participated in this trial: Adriana
Grosman for translation of the manuscript; William Stevenson, MD, for revision
of the manuscript; and Roemmers Argentina Laboratory, Buenos Aires, Argen-
tina for its cooperation.
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